? ? The long-term goal of this research project is to develop effective strategies for the prevention of prostate cancer progression to androgen independence. Our approach to the effective prevention of prostate cancer progression is the use of combination of physical exercise and low doses of chemopreventive agents. Preliminary studies from our laboratory showed that voluntary exercise inhibited the progression of androgen- dependent LNCaP tumors in severe combined immunodeficient (SCID) mice to androgen independence. We also found that a cholesterol-lowering drug Lipitor (atorvastatin) in combination with the cyclooxygenase-2 (Cox-2) inhibitor Celebrex (celecoxib) more potently inhibited the androgen-independent growth of LNCaP tumors in SCID mice than either agent alone. In addition, treatment of cultured LNCaP cells with serum from exercised mice in combination with low doses of Lipitor and Celebrex resulted in a marked growth inhibition and apoptosis induction. We propose combining voluntary exercise with low doses of Lipitor and Celebrex for prevention of prostate cancer progression. We hypothesize that voluntary exercise will strongly enhance the preventive efficacy of Lipitor and Celebrex on prostate cancer progression to androgen independence by synergistic growth inhibition and apoptosis induction in prostate cancer cells. We also hypothesize that the beneficial influence of voluntary exercise on the preventive efficacy of Lipitor and Celebrex is mediated by modulation of inflammation-related cytokines leading to synergistic inhibition of Akt, Erk1/2 and NF-:B survival pathways.
The specific aims are: (1) Determine the preventive efficacy and mechanisms of Lipitor, Celebrex or voluntary exercise alone or in combination on the progression of androgen-dependent LNCaP tumors to androgen independence. (2) In-depth mechanistic studies on the effects of Lipitor, Celebrex, serum from exercised mice and cytokines modulated by exercise on the progression of cultured androgen-dependent LNCaP and CWR22Rv1 cells to androgen independence. Understanding the molecular mechanisms of action for voluntary exercise in combination with Lipitor and Celebrex in prostate carcinogenesis may reveal key molecular targets for future rational design of synergistic combinations of preventive regimens. We anticipate that the anti-carcinogenesis effect of voluntary exercise in combination with Lipitor and Celebrex will have great utility in human cancer prevention. ? ? ?
There is no effective treatment for patients with advanced androgen-independent prostate cancer, and the mortality rate of this disease has steadily increased. We propose combining physical exercise with low doses of Lipitor and Celebrex for prevention of prostate cancer progression. We will determine the preventive efficacy and mechanisms of physical exercise in combination with low doses of Lipitor and Celebrex on androgen- independent progression of prostate cancer. Our research may lead to the development of novel and effective combination prevention for prostate cancer.
|Huang, Huarong; Liu, Ting; Guo, Junxi et al. (2017) Brefeldin A enhances docetaxel-induced growth inhibition and apoptosis in prostate cancer cells in monolayer and 3D cultures. Bioorg Med Chem Lett 27:2286-2291|
|Chen, Xuan; Liu, Yue; Wu, Jian et al. (2016) Mechanistic Study of Inhibitory Effects of Atorvastatin and Docetaxel in Combination on Prostate Cancer. Cancer Genomics Proteomics 13:151-60|
|Huang, Huarong; Cui, Xiao-Xing; Chen, Shaohua et al. (2014) Combination of Lipitor and Celebrex inhibits prostate cancer VCaP cells in vitro and in vivo. Anticancer Res 34:3357-63|
|Zheng, Xi; Cui, Xiao-Xing; Gao, Zhi et al. (2011) Inhibitory effect of dietary atorvastatin and celecoxib together with voluntary running wheel exercise on the progression of androgen-dependent LNCaP prostate tumors to androgen independence. Exp Ther Med 2:221-228|
|Suh, Dong-Churl; Powers, Christopher A; Barone, Joseph A et al. (2010) Full costs of dispensing and administering fluorouracil chemotherapy for outpatients: A microcosting study. Res Social Adm Pharm 6:246-56|
|Zheng, Xi; Cui, Xiao-Xing; Gao, Zhi et al. (2010) Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence. Cancer Prev Res (Phila) 3:114-24|